Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1145-1152

  Lukka, Pradeep B ^a,b   Paxton, James W ^b   Kestell, Philip ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Benzonaphthyridine; Cancer; Lc ms; Pharmacokinetics; SN 28049; Topoisomerase poison

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N [2 (DIMETHYLAMINO)ETHYL] 2,6 DIMETHYL 1 OXO 1,2 DIHYDROBENZO[B] 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; SN 28049; UNCLASSIFIED DRUG; DNA TOPOISOMERASE (ATP HYDROLYSING); N (2 (DIMETHYLAMINO)ETHYL) 2,6 DIMETHYL 1 OXO 1,2 DIHYDROXYBENZO(B) 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; N-(2-(DIMETHYLAMINO)ETHYL)-2,6-DIMETHYL-1-OXO-1,2-DIHYDROXYBENZO(B)-1,6-NAPHTHYRIDINE-4-CARBOXAMIDE; NAPHTHYRIDINE DERIVATIVE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; C57BL 6 MOUSE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADENOCARCINOMA; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; C57BL MOUSE; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE II; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NAPHTHYRIDINES; TISSUE DISTRIBUTION;

EID: 77951901179     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1123-5     Document Type: Article

References (16)

1. Dalgliesh CE, Todd AR (1949) Actinomycin. Nature 164:830
2. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259
3. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumour activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)- phenylamino]-4-acridinecarboxamide. Cancer Res 44:3245-3251
4. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumour agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino) ethyl]-acridine-4-carboxamide. J Med Chem 30:664-669
5. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW (1997) The potential of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide] to circumvent three multidrugresistance phenotypes in vitro. Cancer Chemother Pharmacol 39:424-430
6. McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44:39-44
7. Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, Rampling R, Sorio R, Lacombe D, de Balincourt C, Fumoleau P (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol 13:777-780
8. Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, Paoletti X, Hermans C, Lacombe D, Fumoleau P (2003) Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer 39:330-334 (Pubitemid 36140050)
9. Caponigro F, Dittrich C, Sorensen JB, Schellens JH, Duffaud F, Paz Ares L, Lacombe D, de Balincourt C, Fumoleau P (2002) Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer 38:70-74
10. Deady LW, Rodemann T, Zhuang L, Baguley BC, Denny WA (2003) Synthesis and cytotoxic activity of carboxamide derivatives of Benzo[b] [1, 6]naphthyridines. J Med Chem 46:1049-1054
11. Bridewell D, Porter A, Finlay G, Baguley B (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol 62:753-762
12. Deady LW, Rogers ML, Zhuang L, Baguley BC, Denny WA (2005) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1, 6]naphthyridin-(5H) ones. Bioorg Med Chem 13:1341-1355
13. Lukka PB, Kestell P, Paxton JW, Baguley BC (2008) Development, validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent iV-[2-(dimethylamino) ethyl]-2, 6-dimethyl-1-oxo-1, 2-dihydrobenzo[b]-1, 6-naphthyridine-4-carboxamide (SN 28049). J Chromatogr B 875:368-372
14. Formelli F, Carsana R, Pollini C (1986) Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice. Cancer Chemother Pharmacol 16:15-21
15. Paxton JW, Young D, Evans SMH, Robertson IGC, Kestell P (1993) Tumour profile of iV-[2-(dimethylamino) ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Cancer Chemother Pharmacol 32:320-322
16. Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IGC, Baguley BC (1989) Disposition of amsacrine and its analogue 9-([2-Methoxy-4- [(methylsulfonyl)-amino]phenyl]amino) - N, 5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res 50:503-508